Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Meghan D Storlie"'
Autor:
Philip D Greenberg, Christopher A Klebanoff, Kim Nguyen, Gary Shapiro, Joshua Francis, Cheryl Black, Anthony Thomas, Meghan D Storlie, Allison P Drain, Nicholas Rouillard, Nathaniel Swanson, Santosh Narayan, Tyler Warner, Nicole Danek, Ken Gareau, James Parsons, Jinsheng Liang, Luhua Shen, Tanya Tetrault, Vince Nguyen, Iqraa Priyata, Sarah Vidyasagar, Xingyue He, Patrick J Browne, Rebecca C Lamothe, Gregory J Cost, Thomas M Schmitt, Smita S Chandran, Ankit Gupta, Damien Hallet, Loic Vincent
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7bb2d3e90f9f44b38eb43af51b8a6f42
Autor:
Philip D Greenberg, Christopher A Klebanoff, Kim Nguyen, Gary Shapiro, Joshua Francis, Cheryl Black, Anthony Thomas, Meghan D Storlie, Allison P Drain, Nicholas Rouillard, Nathaniel Swanson, Santosh Narayan, Tyler Warner, Nicole Danek, Ken Gareau, James Parsons, Jinsheng Liang, Luhua Shen, Tanya Tetrault, Vince Nguyen, Iqraa Priyata, Sarah Vidyasagar, Xingyue He, Patrick J Browne, Rebecca C Lamothe, Gregory J Cost, Thomas M Schmitt, Smita S Chandran, Ankit Gupta, Damien Hallet, Loic Vincent
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/cf7222b351e14e179116c6bbe6cf91f4
Autor:
Travis S Young, Mark J Osborn, Bruce R Blazar, Michael Jensen, Christopher A Pennell, Heather Campbell, Sophie Viaud, Meghan D Storlie, Sara Bolivar-Wagers, Yosef Refaeli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Current Food and Drug Administration (FDA)-approved CD19-specific chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies are constitutively active and while efficacious, can cause morbidity and mortality. Their toxicities might be r
Externí odkaz:
https://doaj.org/article/ed50d02bfc084d5ea6b825836143728f
Autor:
Rebecca C. Lamothe, Meghan D. Storlie, Diego A. Espinosa, Rachel Rudlaff, Patrick Browne, Jason Liu, Andres Rivas, Audra Devoto, Jennifer Oki, Ashcon Khoubyari, Daniela S. Aliaga Goltsman, Jyun-Liang Lin, Cristina N. Butterfield, Christopher T. Brown, Brian C. Thomas, Gregory J. Cost
Publikováno v:
The CRISPR Journal.
Autor:
Christopher A Pennell, Heather Campbell, Meghan D Storlie, Sara Bolivar-Wagers, Mark J Osborn, Yosef Refaeli, Michael Jensen, Sophie Viaud, Travis S Young, Bruce R Blazar
Publikováno v:
Journal for immunotherapy of cancer. 10(12)
Current Food and Drug Administration (FDA)-approved CD19-specific chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies are constitutively active and while efficacious, can cause morbidity and mortality. Their toxicities might be r
Autor:
Victor G. Young, Paul J. Fischer, Shuruthi Senthil, Matthew V. Vollmer, Meghan D. Storlie, Jeremy T. Stephan, McKinley L. Swift, Emily T. Chan
Publikováno v:
Dalton Transactions. 47:6166-6176
A series of zerovalent group VI metal complexes of tris(diisopropylphosphinomethyl)phenylborate ([PhB(CH2PiPr2)3]-, PhBPiPr3), including [PPN][M(CO)3(PhBPiPr3)] (M = Cr, Mo, W) and the first bimetallics in which PhBPiPr3 serves as a bridging ligand v
Autor:
Cristina N. Butterfield, Meghan D. Storlie, Diego A. Espinosa, Brian C. Thomas, Gregory J. Cost, Andres Rivas, Rebecca C. Lamothe, Lisa Alexander, Daniela S. Aliaga Goltsman, Christopher T. Brown
Publikováno v:
Blood. 138:3984-3984
Gene-editing technology has revolutionized molecular therapeutics, enabling DNA-engineering-based approaches to treat disease. Despite this, development of medicines using gene editing has been hampered by technological, immunological, and legal limi
Autor:
Yosef Refaeli, Jessie L. Barnum, Angela Panoskaltsis-Mortari, Jeffrey S. Miller, Heather Campbell, Zhengming Xiong, Govindarajan Thangavelu, Scott N. Furlan, Mark J. Osborn, Megan J. Riddle, Michael C. Jensen, Christopher A. Pennell, Cameron McDonald-Hyman, Bruce R. Blazar, Leslie S. Kean, Meghan D. Storlie, Michael Loschi, Jakub Tolar
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 26(6)
The clinical success of chimeric antigen receptor (CAR) T cell therapy for CD19(+) B cell malignancies can be limited by acute toxicities and immunoglobulin replacement needs due to B cell aplasia from persistent CAR T cells. Life-threatening complic